In developed markets, especially the US, pharmaceutical companies are facing a period of uncertainty, with pricing and reimbursements concerns causing significant barriers to revenue potential.
A regulatory advisory group — sponsored by the City of London Corporation and TheCityUK — has hatched a plan for the UK to retain EU market access post-Brexit.
The launch of the Markets in Financial Instruments Directive (MiFID) II is fast approaching.
A lot of negative chatter around energy drinks is unsubstantiated, but the sheer quantity of stories cannot be denied.
Cannabis is increasingly affecting all aspects of retail in the US.